Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases.
$3.22 -0.39 (-10.80%)
As of 06/28/2022 15:59:57 EST IEX book CBOE book
2022 © Stock Market MBA, Inc.